Ashkon Software



CBMX - CombiMatrix Corporation

CombiMatrix Corporation logo CombiMatrix Corporation (CBMX) is a biotechnology company that specializes in the development of diagnostic tests and services for prenatal and postnatal genetic abnormalities. The company's focus is on the development of its flagship product, the CombiSNP microarray-based diagnostic test, which is designed to detect chromosomal abnormalities in fetuses.

The CombiSNP test is used to screen for chromosomal abnormalities that can lead to genetic disorders such as Down syndrome, as well as to identify potential genetic risks for other conditions. The test is also used to help identify the cause of recurrent miscarriages.

In addition to the CombiSNP test, CombiMatrix offers a range of genetic testing services, including pre-implantation genetic diagnosis (PGD) and array comparative genomic hybridization (aCGH). The company's PGD services are used to screen embryos prior to in vitro fertilization (IVF) to identify those with genetic abnormalities. The aCGH service is used to detect genetic abnormalities in cancer cells and to help identify the best course of treatment.

CombiMatrix operates in the United States and internationally, with laboratories located in Irvine, California and Hyderabad, India. The company's customer base includes healthcare providers, IVF clinics, and research institutions.

CombiMatrix was founded in 1995 and went public in 2006. In 2017, the company was acquired by Invitae Corporation, a leading provider of genetic testing services. The acquisition was seen as a strategic move by Invitae to expand its product offerings and increase its customer base.

Overall, CombiMatrix's focus on developing diagnostic tests for genetic abnormalities positions the company well to benefit from the growing demand for personalized medicine and genetic testin




Copyright © 2000-2023, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer